Candel Therapeutics annual revenue
2020
2021
2022
2023
2024
2025
Candel Therapeutics Revenue Growth & History (CADL)
Candel Therapeutics reported $0 in revenue for fiscal 2025.
View full Candel Therapeutics company overviewCandel Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | $0 | — |
| 2024 | 2024-12-31 | $0 | $0 | — |
| 2023 | 2023-12-31 | $0 | −$125,000 | −100.00% |
| 2022 | 2022-12-31 | $125,000 | $0 | 0.00% |
| 2021 | 2021-12-31 | $125,000 | $0 | 0.00% |
| 2020 | 2020-12-31 | $125,000 | — | — |
Candel Therapeutics quarterly revenue
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | $0 | — |
| Q4 2025 | 2025-12-31 | $0 | — | — |
| Q3 2025 | 2025-09-30 | $0 | — | — |
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q1 2025 | 2025-03-31 | $0 | — | — |
| Q4 2022 | 2022-12-31 | $32,000 | $0 | 0.00% |
| Q3 2022 | 2022-09-30 | $31,000 | $0 | 0.00% |
| Q2 2022 | 2022-06-30 | $31,000 | $0 | 0.00% |
| Q1 2022 | 2022-03-31 | $31,000 | $0 | 0.00% |
| Q4 2021 | 2021-12-31 | $32,000 | — | — |
| Q3 2021 | 2021-09-30 | $31,000 | $0 | 0.00% |
| Q2 2021 | 2021-06-30 | $31,000 | $0 | 0.00% |
| Q1 2021 | 2021-03-31 | $31,000 | — | — |
| Q3 2020 | 2020-09-30 | $31,000 | — | — |
| Q2 2020 | 2020-06-30 | $31,000 | — | — |
Candel Therapeutics revenue growth trends
Candel Therapeutics's latest reported quarter, Q2 2026, generated $0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Candel Therapeutics source filings ↗